Novartis: US $16 billion acquisition of GSK's cancer medicine business
-
Last Update: 2015-05-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Tencent finance 2015-5-5 according to Bloomberg, Novartis agreed to buy GlaxoSmithKline's cancer drug business for up to $16 billion, set up a consumer healthcare joint venture with GlaxoSmithKline, and sell its animal medical subsidiary to Lilly for $5.4 billion On May 4, Novartis said in a statement that it would also sell its vaccine business other than influenza to GlaxoSmithKline for $7.1 billion This includes royalties and up to $1.8 billion in consideration for meeting specific business objectives.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
